UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1386-4
Program Prior Authorization/Notification
Medication Omnipod® 5, TwiistTM
P&T Approval Date 5/2022, 6/2023, 6/2024, 3/2025
Effective Date 6/1/2025
1. Background:
External insulin pumps are used for managing individuals with diabetes and deliver insulin by
continuous subcutaneous infusion. OmniPod 5 is indicated for management of type 1 diabetes
in persons aged 2 and older and in persons with type 2 diabetes aged 18 and older. Twiist is
indicated in persons aged 6 and older with type 1 diabetes. Members will be required to meet
the following coverage criteria.
2. Coverage Criteriaa:
A. Initial Authorization
1. Omnipod 5 or Twiist will be approved for initial therapy based on both of the
following criteria:
a. One of the following:
(1) For Omnipod 5: Diagnosis of diabetes
(2) For Twiist: Diagnosis of Type 1 diabetes
-AND-
b. Both of the following:
(1) Patient or caregiver is motivated to assume responsibility for self-care and
insulin management.
(2) Patient or caregiver demonstrates knowledge of importance of nutrition
including carbohydrate counting and meal planning.
Authorization will be issued for 12 months.
B. Reauthorization
1. Omnipod 5 or Twiist will be approved for continuation of therapy based on the
following criteria:
a. Documentation of positive clinical response
Authorization will be issued for 12 months.
© 2025 UnitedHealthcare Services, Inc.
1
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
• Coverage is not provided for indications unproven per medical benefit drug policy.
4. References:
1. American Diabetes Association. Diabetes Technology: Standard of Medical Care in
Diabetes - 2024. Diabetes Care 2024;47(supplement 1):S126-S144.
2. American College Of Clinical Endocrinology Consensus Statement: Comprehensive Type 2
Diabetes Management Algorithm- 2023 Update. Endocrine Practice 29(2023)305-340.
Program Prior Authorization/Notification – Omnipod 5
Change Control
5/2022 New program.
6/2023 Annual review. Updated references.
6/2024 Annual review. Updated references.
3/2025 Added Twiist to criteria.
© 2025 UnitedHealthcare Services, Inc.
2